Sodium Valproate + Valproic Acid Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) Injection
Available Strengths: 100 mg/mL
Reference Brands: Depacon (Valproate IV)(US)
Category:
Antipsychotropic Drugs
Sodium Valproate + Valproic Acid is a key treatment for epilepsy and bipolar disorder, available in oral and IV forms. With global brands like Epilim Chrono and Depakote, it’s a high-demand neuropsychiatric product. Pharma B2B buyers source this from GMP-approved manufacturers for international markets.
Sodium Valproate + Valproic Acid is available in Intravenous (IV) Injection
and strengths such as 100 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sodium Valproate + Valproic Acid is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sodium Valproate + Valproic Acid can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sodium Valproate + Valproic Acid combination is widely prescribed for the management of epilepsy, bipolar disorder, and migraine prophylaxis. This dual formulation ensures rapid and sustained release, improving therapeutic outcomes. Available in oral (200 mg, 300 mg, 500 mg) and injectable forms (100 mg/mL), it is marketed under popular brands like Epilim Chrono in the EU and Depakote equivalents in the US. Pharmaceutical exporters and distributors globally source this product from GMP-certified manufacturers due to its proven efficacy and consistent market demand. Ideal for neuropsychiatric B2B portfolios, it offers stable market opportunities for generics and branded suppliers.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing